



ANNUAL RESULTS 2012

STAR CONFERENCE March 26th, 2013

Company Presentation



Disclaimer

Certain statements in this slide show, including those addressing the Company's beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward-looking statements. Forward-looking statements involve known or unknown risks, including general economic and business conditions, and conditions in the industry we operate and may be affected should our assumptions turn out to be inaccurate. Consequently, no forward-looking statement can be guaranteed and actual future results, performance, or achievements may vary materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation about the contents nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof.







- 1. THE GLOBAL LASER MARKET
- 2. CYNOSURE
- 3. EL.EN. GROUP
- 4. LASER SURGERY
- 5. 2012 FINANCIAL RESULTS
- **6.** 2013 GUIDANCE
- 7. MULTIPLES





The Global Laser Market





LASER


Light Amplification Stimulated by Emission of Radiation

MEDICAL LASER Systems

INDUSTRIAL LASER Systems



The MEDICAL Laser Market





The INDUSTRIAL Laser Market

Laser Sources Market

Revenues (\$M)



2008 2009 2010 2011 2012 2013

Source: Industrial Laser Solutions





Cynosure





November 2012: Sale of shares

Nr. of shares sold 840.000 Nr. of residual shares 2.098.628

	Consolidated	El.En. S.p.a
Proceeds	12.876	12.876
Capital Gain	5.416	10.038
Shares revaluation	13.530	0
Income taxes	(324)	(138)
Total	18.622	9.900



March 2013: Palomar Acquisition

	Mk Cap.	NFP Dec.,2012		
Tr.	\$/000	\$/000		
Cynosure @ \$27,16	445.479	125.920		
Palomar @ \$13,46	268.800	99.707		

\$ 6,825 Price \$13,65 \$ 6,825 Per share in cash. Total amount: \$147 million

Per share in Cynosure common stock.

Newly issued shares: 5,2 million *

Owernship after acquisition:

Cynosure shareholders 77%

Palomar shareholders 23%

El.En. 10%




^{*} Subjected to closing conditions



El.En. Group







Group Overview

High –Tech laser photonics Group

Develops, manufactures and distributes laser sources and laser systems for medical and industrial applications

Know-how based on 30 years stratification of multidisciplinary experience

December , 31st 2012: Consolidated Revenues of €151 mln, up 10% YoY, 812 employees

Global positioning



Strategic Strengths

Multidisciplinary and multifacility R&D activity: sources, systems, applications

Covering both Medical and Industrial laser markets

Raising technological entry barriers through R&D

Industrial

✓ Combine High tech laser source development with flexible production facilities in high growth areas


Medical

- ✓ Maximize market penetration by multi brand approach
- ✓ Open new market segments by developing innovative applications
- ✓ Leverage worldwide distribution





Consolidated Revenues





R&D Activity

Clinical trials and validations of new therapeutic laser treatments and research on new applications of laser-tissue interaction

Need to raise entry barriers: Technology / clinical

Laser systems for regenerative medicine

Strengthening of PHOTOBIOLAB

New applications of cutting edge CO₂ platform: MonaLisa Touch, ENT

Surgical lasers for BPH: High Power Tm and Ho:YAG

Laser cutting systems with high power sources

Compact RF medium power sources

Patents development



Medical/Aesthetic

Aesthetic

Hair Removal

Vascular Lesions

Skin Rejuvenation

Pigmented Lesions

Treatment of Cellulite

Acne

Tattoo Removal

Anti - Aging

LaserBody Sculpting

Removal of Unwanted Fat













Medical

Gynaechology

Endovascular

Dermatology

Psoriasis and Vitiligo

Dentistry

Therapy

General Surgery

Urology

ENT





LASER SURGERY



P. Salvadeo CEO Quanta System S.p.A.

Laser Surgery

Laser Surgery – a less crowded market ...

- Fewer competitors than the aesthetic market :
 - BPH lasers: only 6 major manufacturers worldwide
 - Lithotripsy: about 20 marketers but only 7 manufacturers
 - Other surgical procedures: only 5 manufacturers
 - Minor surgical interventions: the Group has complete laser product line
 - CO2 laser: Several manufacturers, few with top quality accessories (i.e micromanipulators)

Easy Spot Micromanipulator





- Top OEM partners
- Mobile service companies (USA)




Surgical laser market

Applications	Technology	Units/year	Global Sales	El.En. Group ma	rket shares		
Lithotripsy	Medium power Ho	1.000	35 M Euro	Quanta System + OEM - 17,6%			
ВРН	Green/Ho/Thulium	380	33,5 M Euro	Quanta Syste	Quanta System - Asclepion - 8,7%		
Other high power lasers	Diodes	100	4,5 M Euro	Quanta System - 4,8%			
Small surgeries	Diodes	1.600	24 M Euro	Quanta System - 14,25%			
ENT / GYN	CO2	1.600	45 M Euro		Deka - 5%		
FIBERS (disposables)	Fibers	280.000	224 M Euro	Quar	Quanta - Asclepion - 2,8%		
TOTAL			366 M Euro	El.En. Group - 5,2%			
Source: Market Tracks report, CMS Global Mark		ification case data	395	435	480		
2012/2015	CAGR = 9%	2012	2013	2014	2015		


Urology

BPH and Stones






Lithotripsy



Holmium: YAG Laser

Gold standard


for stones







Thulium 117 µm 114 µm



Thulium laser for Benign Prostate Hyperplasia (BPH)?


- Extremely safe
- Very effective for vaporization and cutting
- Highest grade of speed and haemostasis
- Very confined coagulation
- Almost no perioperative morbidities
- No post-procedureal transfusion
- Minimal hospitalization time
 (1 day vs. 4 days for traditional TURP technique)

Significantly decreases catheterization time, hospital stay and blood loss over traditional TURP.



USA Market


USA - **BPH Market Segmentation**




Source: Market Tracks report, CMS Reimbursement and ABU certification case data



USA Market





Source: Market Tracks report, CMS Reimbursement and ABU certification case data





New Patent


TURP → LASER TURP













Other surgical projects

Thoracic Surgery

- INTERLOBAR FISSURE
- PULMONARY LOBECTOMY
- LASER PULMONARY ANATOMIC RESECTION
- ENUCLATION OF TUMOR without Stapler





2012 Financial Results





Consolidated P&L

		31/12/11		31/12/12		Var.%
				unaudited		
	Revenues	137.392	100,0%	151.234	100,0%	10,1%
	Gross margin	67.137	48,9%	72.050	47,6%	7,3%
	EBITDA	10.823	7,9%	12.519	8,3%	15,7%
	EBIT	5.094	3,7%	7.474	4,9%	46,7%
	Income before taxes	4.765	3,5%	6.092	4,0%	27,8%
Income from	continuing operations	2.107	1,5%	3.140	2,1%	49,0%
Income from dis	scontinued operations	(2.396)	-1,7%	26.672	17,6%	
	Minority interest	(18)	0,0%	6.613	4,4%	
	Net Income (loss)	(270)	-0,2%	23.199	15,3%	
		31/12/11		31/12/12 unaudited		
	Net financial position	53.035		17.794		
Net financial po	sition (w/o Cynosure)	1.764		17.794		



Discontinued operations

	31/12/11	31/12/12 unaudited
Cynosure contribution Capital Gain & Revaluation Income taxes on capital gain and reval.	(2.396)	8.050 18.946 (324)
Net result from discontinued operations:	(2.396)	26.672




n. – Revenues breakdown by business





Service Medical Industrial

Medical
Aesthetic
Surgical CO₂
Physiotherapy
Dental



2012: +10%

Dec. 31st, 2011


Dec. 31st, 2012


Cynosure

Medical

Aesthetic Service









2013 Guidance







2013 forecast

FORECAST

(current economic situation)

Sales: + 5%

Improvement in EBIT

FORECAST

(improvement in economic situation)

Sales: +10%

EBIT%: >5%





Multiples





El.En. multiples

Stockholder's Equity per share * 26

Price / Book Value 0,59

EV /EBIT (85% EBIT) 1,78

EV / Sales (85% Sales) 0,09

El.En. Market Cap. 74,8 @ €15,5

Net financial position 17,8 @ 31/12/12

Market value of 2,1 mm Cynosure shares 45,7 @ \$28,5 (Euro/Usd=1,31)

Enterprise Value 11,3

Stockholder's Equity net of minorities, 126,4

* (with Cynosure shares at market value)





El.En. SPA

Enrico ROMAGNOLI

Investor Relations Manager

tel. +39 055-8826807

E-mail: finance@elen.it

POLYTEMS HIR SRL

Bianca FERSINI MASTELLONI

Financial Communication

Tel. +39 06-6797849 / +39 06-69923324

E-mail: b.fersini@polytemshir.it

POLYTEMS HIR SRL

Roberta MAZZEO

Press office

Tel. +39 06-6797849 / +39 06-69923324

E-mail: r.mazzeo@polytemshir.it